Holen Sie sich die Stockscreener-App
49.38
0.40%
0.18
Schlusskurs vom Vortag:
$49.20
Offen:
$49.33
24-Stunden-Volumen:
349.28K
Relative Volume:
0.25
Marktkapitalisierung:
$10.55B
Einnahmen:
$1.98B
Nettoeinkommen (Verlust:
$83.59M
KGV:
132.03
EPS:
0.374
Netto-Cashflow:
$502.31M
1W Leistung:
+0.89%
1M Leistung:
+2.78%
6M Leistung:
+24.83%
1J Leistung:
+2.05%
1-Tages-Spanne:
$49.20
$49.49
1-Wochen-Bereich:
$48.62
$49.50
52-Wochen-Spanne:
$37.74
$51.88
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
49.40 | 10.55B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
490.01 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
207.60 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
637.02 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.22 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.90 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
What makes Qiagen N.V. stock price move sharply2025 Stock Rankings & Verified Swing Trading Watchlists - thegnnews.com
QIAGEN NV : Gets a Buy rating from Deutsche Bank - MarketScreener
Qiagen Manager Sells $1.23M in Shares for Asset Allocation - AInvest
QIAGEN Executive Sells Significant Shareholding - TipRanks
Qiagen Executive Sells Significant Shareholding - TipRanks
QIAGEN Manager Sells Shares for Asset Allocation - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
QIAGEN N.V. Announces Managerial Share Sale by Roland Sackers - TipRanks
Qiagen N.V. Reversal Rally May Surprise Bears2025 Stock Rankings & Fast Moving Market Watchlists - metal.it
Upbeat Q2 Results and Raised Outlook Could Be a Game Changer for Qiagen (QGEN) - simplywall.st
Sector Leaders Rotate Capital Into Qiagen N.V.July 2025 Spike Watch & AI Based Buy/Sell Signal Reports - newsyoung.net
Qiagen N.V. shares rise 1.09% intraday as DAX index climbs toward record high. - AInvest
Will Qiagen N.V. Hold Gains Into CloseJuly 2025 Fed Impact & Growth Focused Investment Plans - sundaytimes.kr
Sentiment Turns Positive on Qiagen N.V. — Reversal AheadJuly 2025 Movers & Long-Term Capital Growth Strategies - classian.co.kr
PATENT—Fed. Cir.: Qiagen did not infringe Labcorp's DNA sequencing preparation patents; $4.7M jury verdict reversed - VitalLaw.com
How Investors Are Reacting To Qiagen (QGEN) Return to Profitability and Upgraded 2025 Sales Outlook - simplywall.st
Contradictions Unveiled: Qiagen's 2025Q2 Earnings Call Highlights Divergent Views on Market Performance and Growth - AInvest
Is Qiagen N.V. stock showing strong momentumFree Trend Reversal Signals - newsyoung.net
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - GlobeNewswire Inc.
Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention - sharewise.com
Investors Interested In Qiagen N.V.'s (NYSE:QGEN) Earnings - 富途牛牛
Europe Molecular Oncology Diagnostics Market Research Report 2024-2033 | Competitive Analysis of Biocartis Group, bioMerieux, F. Hoffmann-La Roche, QIAGEN - Yahoo Finance
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $49 to $50 - 富途牛牛
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Why Qiagen N.V. stock attracts strong analyst attentionMulti-Year Breakout Candidates - sisain.net
QIAGEN Reports Strong Q2 2025 Results, Raises Sales Outlook - The Globe and Mail
UBS Adjusts Price Target on QIAGEN to $50 From $48, Maintains Neutral Rating - MarketScreener
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $50 to $55 - 富途牛牛
UBS Maintains Qiagen NV(QGEN.US) With Hold Rating, Announces Target Price $50 - 富途牛牛
Qiagen N.V. (NYSE:QGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
QIAGEN NV : Jefferies maintains a Buy rating - MarketScreener
Qiagen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Qiagen N.V. shares rise 1.16% premarket after Deutsche Bank reaffirms Buy rating and Q2 earnings beat expectations. - AInvest
QIAGEN Exceeds Q2 2025 Outlook with 7% Sales Growth and Improved Profitability - AInvest
Transcript : Qiagen N.V., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Qiagen: Better than expected Q2; sales guidance upgraded - MarketScreener
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - MarketScreener
Activist investor Fivespan takes stake in QiagenBloomberg - MSN
Qiagen N.V. shares fall 1.22% premarket despite exceeding Q2 2025 outlook with solid growth. - AInvest
Qiagen NV Reports Strong Q2 Earnings, Surpasses Revenue ExpectationsNews and Statistics - IndexBox
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability - BioSpace
Qiagen: Q2 Earnings Snapshot - The Washington Post
Qiagen (QGEN) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Qiagen NV reports results for the quarter ended June 30Earnings Summary - TradingView
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability | QGEN Stock News - GuruFocus
Qiagen reports Q2 adjusted EPS 62c, consensus 60c - TipRanks
Qiagen reports Q2 2025 net sales $534 million, adjusted EPS $0.6 - MarketScreener
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk - simplywall.st
What to Expect from Qiagen NV (QGEN) Q2 2025 Earnings - GuruFocus
Can Qiagen N.V. Escape Recent Bear ChannelRisk Managed Trade Playbook Insight - beatles.ru
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):